Generate Biomedicines, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Generate Biomedicines, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-13.4×Operating cash was negative last year, while some debt falls due within a year.
Higher than 52% of Healthcare companies in United States.
Cash Cushion Ratio
+10%Cash, after subtracting all debt, equals 10% of its market value (net cash).
Higher than 50% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Generate Biomedicines, Inc. made a loss over the last year. Generate Biomedicines, Inc. owes $0.19 for every $1 it owns. Generate Biomedicines, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGenerate Biomedicines, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.49The share price is 3.49 times Generate Biomedicines, Inc.'s book value per share, higher than 61% of Healthcare companies in United States.
Market cap
$1.6 BThe total market value of all of Generate Biomedicines, Inc.'s shares at today's price (share price × number of shares), larger than 70% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$456 MWhat Generate Biomedicines, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.55Net worth divided by the number of shares. The share price of $12.41 is 3.5 times this, which is the P/B above.
Owes vs Owns
0.19×Generate Biomedicines, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Dividend yield
NoneGenerate Biomedicines, Inc. does not currently pay a dividend.
Revenue growth
+56%Revenue rose 56% in the year to Dec 2025.
Profit growth
LossGenerate Biomedicines, Inc. made a loss in each of the last two years.
Profit margin
-637.0%Generate Biomedicines, Inc. lost $637 for every $100 of revenue.
Interest cover
Not coveredGenerate Biomedicines, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashGenerate Biomedicines, Inc. held $153 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Generate Biomedicines, Inc.: $1.6 B ÷ $456 M (30 Jun 2026) = 3.5.
How much does Generate Biomedicines, Inc. owe compared with what it owns?
Generate Biomedicines, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Does Generate Biomedicines, Inc. pay a dividend?
No. Generate Biomedicines, Inc. does not currently pay a dividend.
Is Generate Biomedicines, Inc.'s revenue growing?
Revenue rose 56% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.